Effects of Combination of Anti-CTLA-4 and Anti-PD-1 on Gastric Cancer Cells Proliferation, Apoptosis and Metastasis
Background/Aims: Gastric cancer (GC) is one of the most common and lethal varieties of cancers. Anticancer activities of anti-CTLA-4 and anti-PD-1 antibodies have been explored in different cancers, including GC. The study aimed to explore the role of combination therapy with anti-CTLA-4 and anti-PD...
Main Authors: | Bin Wang, Lei Qin, Mei Ren, Hao Sun |
---|---|
Format: | Article |
Language: | English |
Published: |
Cell Physiol Biochem Press GmbH & Co KG
2018-08-01
|
Series: | Cellular Physiology and Biochemistry |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/492876 |
Similar Items
-
Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
by: Amirali Karimi, et al.
Published: (2021-03-01) -
Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies
by: Sonam Puri, et al.
Published: (2020-01-01) -
Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1
by: Yi-Chi eKong, et al.
Published: (2014-05-01) -
Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
by: Muhammad Zubair Afzal, et al.
Published: (2018-07-01) -
Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells
by: Adriana Amaro, et al.
Published: (2023-03-01)